Table 4 Results of the sensitivity analyses after excluding patients who received urokinase within two days of initiating VA-ECMO
Weighted cohort | ||||
|---|---|---|---|---|
Monteplase | Control | Risk differences | ||
Outcomes | (n = 289) | (n = 786) | (95% CI) | P-value |
Primary outcome | ||||
In-hospital mortality, n (%) | 159 (55) | 465 (59) | − 4.1 (− 11.6 to 3.4) | 0.28 |
Secondary outcomes | ||||
Favorable neurological outcomes, n (%) | 117 (41) | 271 (34) | 6.1 (− 1.3 to 13.4) | 0.11 |
Length of hospital stay, days, mean (SD) | 24 (31) | 23 (32) | 0.7 (− 3.7 to 5.0) | 0.77 |
Length of VA-ECMO, days, mean (SD) | 3 (3) | 3 (4) | − 0.4 (− 0.9 to 0.06) | 0.09 |
Total hospitalization cost, × 103 dollars, mean (SD) | 29 (19) | 27 (21) | 1.6 (− 1.3 to 4.5) | 0.28 |
Major bleeding in a critical area or organ, n (%) | 28 (10) | 21 (3) | 6.9 (1.7 to 12.1) | 0.01 |
Intracranial bleeding, n (%) | 12 (4) | 8 (1) | 3.1 (− 0.9 to 7.2) | 0.13 |
Blood transfusions, ml, mean (SD) | ||||
Red blood cells | 2903 (2722) | 2635 (2821) | 268 (− 179 to 715) | 0.24 |
Fresh-frozen plasma | 1505 (1733) | 1414 (2030) | 92 (− 196 to 380) | 0.53 |
Platelet concentrate | 265 (446) | 297 (555) | − 31 (− 103 to 40) | 0.39 |